tirzepatide clear lake 15mg Tirzepatide Medical Weight Loss Therapy

Since 2019, GLP-1 treatments for non-diabetic purposes have increased 700%, according to the investment analysis firm Morningstar Equity Research, which projects the market for GLP-1s will reach $180 billion in 2034

Severe Safety Concerns Patients with extreme gastrointestinal distress, including pancreatitis and gallbladder issues, may need hospitalization to stabilize their condition

The data available for exenatide showed less of a risk towards thyroid cancer than liraglutide, but to better quantify the risk the FDA has required Amylin to conduct additional rodent studies to better identify the thyroid issue

Insulin sensitivity often decreases